Eltrombopag in a short regimen for three days was efficacious to restore the PLT count in DF and DHF patients.

administration of eltrombopag in a short regimen for three days was efficacious to restore the PLT count in DF and DHF patients. The hi

DENGUE

Recombinant tetravalent dengue vaccine Dengvaxia® (CYD-TDV)

Safety of CYD-TDV dengue vaccine

https://www.who.int/vaccine_safety/committee/topics/dengue/Aug_2015/en/

SAGE concluded that for countries considering vaccination as part of their dengue control program, a “pre-vaccination screening strategy” would be the preferred option, in which only dengue-seropositive persons are vaccinated.

In the absence of data on vaccine efficacy and safety with fewer than three doses, CYD-TDV is recommended as a three-dose series given 6 months apart.

https://www.who.int/immunization/research/development/dengue_q_and_a/en/

Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9–50 years (CYD65)

A two-dose CYD-TDV regimen might be an alternative to the licensed three-dose regimen in individuals who are dengue seropositive at baseline and aged 9 years and older. Vaccination with a reduced number of doses could lead to improved vaccine compliance and coverage, especially in low-resource settings.